Business Context and Reporting Period
Company: Tempest Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 11, 2025
Event: Suspension and termination of the ATM Prospectus Supplement dated February 6, 2025, related to the Open Market Sale Agreement with Jefferies LLC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate action regarding securities issuance.
Material Changes
- ATM Program Status: The Company suspended and terminated the prospectus supplement for its At-The-Market (ATM) equity offering program effective June 11, 2025.
- Sales Agreement Status: The underlying Open Market Sale Agreement with Jefferies LLC remains in full force and effect, but no sales of securities will occur under this agreement until a new prospectus or registration statement is filed.
Guidance, Outlook, and Risks
Management Commentary: The Company notified Jefferies LLC of the suspension to halt sales of common stock under the current prospectus supplement. No new sales will be made until regulatory documentation is updated.
Risks/Contingencies: The filing does not disclose specific financial risks or contingencies beyond the operational pause in the equity offering program.
Investor Verification Checklist
- Confirm the status of the Open Market Sale Agreement with Jefferies LLC (active but paused for sales).
- Monitor for the filing of a new prospectus supplement or registration statement required to resume ATM sales.
- Review recent 10-Q or 10-K filings for the most current financial position, as this 8-K contains no financial data.